IPO: Amylyx Pharmaceuticals, Inc. Date: 07 January 2022

Symbol: AMLX
Industry: Health Care
Exchange: NASDAQ
IPO Price Low: $18
IPO Price High: $20

Amylyx Pharmaceuticals’ mission is to develop therapies that change the treatment paradigm for amyotrophic lateral sclerosis, or ALS, and a broad range of neurodegenerative diseases by keeping neurons alive. We are pursuing commercialization of our product candidate, AMX0035, which we believe is the first drug candidate to show both a functional and survival benefit in a large-scale clinical trial of patients with ALS. We are actively pursuing regulatory approvals of AMX0035 for the treatment of ALS in Canada, the United States and Europe. We have recently initiated a Phase 3 clinical trial of AMX0035 for the treatment of ALS at clinical trial sites in the United States and Europe.

Shares Offered: 10000000
Shares Outstanding: 56273487
Market Cap: 1069196253

How to buy Amylyx Pharmaceuticals, Inc. stock

For more information on the Amylyx Pharmaceuticals, Inc. IPO please sign up using the form opposite.

IPO Exchange is dedicated to providing accurate information to help you make the best investment decisions and expand your portfolio.

Get more details on how you can invest in Amylyx Pharmaceuticals, Inc. by signing up below.